Japan Tobacco (JAPAF) 35.5500 $JAPAF
Renal Anemia Pipeline Review, H1 2015 - 24 Companies & 20 Drug Profiles
M2 - Thu Jul 09, 6:29AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rspq67/renal_anemia) has announced the addition of the "Renal Anemia - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Renal Anemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Renal Anemia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - 3SBio Inc. - Acceleron Pharma, Inc. - Akebia Therapeutics, Inc. - Amgen Inc. - Aprogen, Inc. - Bayer AG - BIOCAD - CCM Duopharma Biotech Bhd. - Daiichi Sankyo Company, Limited - Dong-A Socio Group - FibroGen, Inc. - GlaxoSmithKline plc - Hospira, Inc. - Intas Pharmaceuticals Ltd. - Japan Tobacco Inc. - JCR Pharmaceuticals Co., Ltd. - Jiangsu Hansoh Pharmaceutical Co., Ltd. - Medgenics Inc. - Myungmoon pharmaceutical Co.,Ltd. - Panacea Biotec Limited - Pieris AG - ProMetic Life Sciences Inc. - Sandoz International GmbH - Zydus Cadila Healthcare Limited Drug Profiles - AKB-6548 - daprodustat - darbepoetin alfa (recombinant) - DS-1093 - EPO-018B - epoetin alfa (recombinant) - FG-2216 - FMX-8 - JTZ-951 - MDGN-201 - MM-P01-01 - molidustat - NuPIAO - PBI-1402 - PBI-4050 - PEG-EPO - PRS-080 - Recombinant Protein for Renal Anemia - roxadustat - sotatercept For more information visit http://www.researchandmarkets.com/research/rs...nal_anemia
MDGN: 6.47 (+0.37), AMGN: 154.10 (+2.79), GSK: 42.45 (+0.65), AKBA: 8.83 (+0.09), FGEN: 22.82 (+0.58), XLRN: 30.03 (+0.20)
Cedar Pollen Allergy - Pipeline Review, H1 2015
M2 - Mon Jun 29, 10:21AM CDT
Research and Markets (http://www.researchandmarkets.com/research/qb7s58/cedar_pollen) has announced the addition of the "Cedar Pollen Allergy - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Cedar Pollen Allergy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cedar Pollen Allergy and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Cedar Pollen Allergy - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Cedar Pollen Allergy and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Cedar Pollen Allergy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Cedar Pollen Allergy pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Mentioned - Allergy Therapeutics plc - Anergis SA - Biomay AG - Circassia Pharmaceuticals plc - Immunomic Therapeutics, Inc. - Japan Tobacco Inc. - REGiMMUNE Corporation - Stallergenes S.A. For more information visit http://www.researchandmarkets.com/research/qb...dar_pollen
New study links smoking to more forms of cancer
Seeking Alpha - at Seeking Alpha - Tue Jun 16, 6:06AM CDT
RAI: 76.87 (+0.77), BTI: 112.52 (+3.75), PM: 82.16 (+0.92), LO: 71.40 (-0.33), MO: 51.31 (+0.36), VGR: 23.92 (+0.29)
Japan Tobacco International | JT Publishes Sustainability Report FY2014
M2 - Mon Jun 15, 8:26AM CDT
Japan Tobacco Inc. (JT) (TSE: 2914) has published the JT Group Sustainability Report FY2014, outlining its sustainability initiatives and performance for the year ending 31st December, 2014.
Philip Morris Offers Attractive Pricing And Growth Potential
J Mintzmyer - at Seeking Alpha - Thu Jun 11, 10:03AM CDT
PM: 82.16 (+0.92), BTI: 112.52 (+3.75)
WisdomTree Japan-Themed ETF Focuses on Growth, Quality
at The Street - Mon Jun 08, 7:22PM CDT
WisdomTree's Japan Dividend Growth ETF is the company's 10th Japan-themed ETF, said its associate director of research.
DXJ: 56.33 (+1.54), JDG: 23.69 (unch), NTT: 36.75 (+1.49), DCM: 19.16 (+0.26)
Global Pollen Allergy Pipeline Review, H1 2015 - 14 Companies & 31 Drug Profiles
M2 - Fri Jun 05, 5:06AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3crnf4/pollen_allergy) has announced the addition of the "Pollen Allergy - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Pollen Allergy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pollen Allergy and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - ALK-Abello A/S - Allergopharma Joachim Ganzer KG - Allergy Therapeutics plc - Anergis SA - Biomay AG - BioTech Tools s.a. - Circassia Pharmaceuticals plc - HAL Allergy BV - Immunomic Therapeutics, Inc. - Japan Tobacco Inc. - Laboratorios LETI S.L. - REGiMMUNE Corporation - Roxall Medizin GmbH - Stallergenes S.A. Drug Profiles - ALK Birch Pollen Vaccine - AllerG - Allergen Extract Of Phleum Pratense - Allergen for Birch Pollen Induced Allergic Rhinitis and Rhinoconjunctivitis - Allergen for Pollen Grass Allergy Induced Allergic Rhinitis and Rhinoconjunctivitis - AllerJ - AllerT - ASP-4070 - Avanz Phleum Pratense - Birch-SPIRE - BM-31 - BM-32 - clustoid wiesenlieschgras - Drug for Birch Pollen Allergy - Drug for Japanese Cedar Pollen Allergy - Drugs for Cedar Pollen Allergy - gpASIT TM - grass allergy vaccine - Japanese cedar hypoallergenic vaccine - JCC-LAMP-Vax - MC-LAMP-Vax - Multi-LAMP-Vax - PL-102 - Pollinex Quattro - rBet v1 - rBet v1-FV - RGI-1001 - timothy grass pollen allergen extract - TO-206 - Vaccine for Asthma, Grass Pollen Allergy and Allergic Rhino-Conjunctivitis - Vaccine for Cedar Pollen Allergy For more information visit http://www.researchandmarkets.com/research/3c...en_allergy
Philip Morris: A New Challenge Emerges
Albert Alfonso - at Seeking Alpha - Wed Jun 03, 1:22PM CDT
PM: 82.16 (+0.92), BTI: 112.52 (+3.75), MO: 51.31 (+0.36)
Reduction seen for massive Canadian tobacco damages award
Seeking Alpha - at Seeking Alpha - Wed Jun 03, 7:13AM CDT
BTI: 112.52 (+3.75)
Tobacco companies face large class-action payments in Canada
Seeking Alpha - at Seeking Alpha - Tue Jun 02, 8:04AM CDT
PM: 82.16 (+0.92), BTI: 112.52 (+3.75)
European Stocks Drop as Greece Debt Talks Get Serious; Inflation Rises
at The Street - Tue Jun 02, 5:37AM CDT
European stock markets declined Tuesday on Greek debt worries even as better-than-expected eurozone consumer price data suggested that government bond-buying had staved off Japanese-style deflation.
PM: 82.16 (+0.92), BTI: 112.52 (+3.75)
Black market tobacco trade increases in the UK
M2 - Thu May 28, 9:33AM CDT
The UK has seen nearly a 50% rise in the consumption of counterfeit and contraband (C&C) cigarettes in 2014, the second highest increase across the whole of the EU according to a KPMG report published today.
PM: 82.16 (+0.92)
56.6 Billion Illegal Cigarettes Consumed in the EU in 2014, Worth More Than EUR11bn in Lost Tax Revenue
Business Wire - Thu May 28, 3:09AM CDT
The scale of the illegal trade in cigarettes remains sizeable in the European Union (EU), with a total of 56.6 billion illegal cigarettes consumed in 2014, representing 10.4% of total consumption, according to the latest annual report by KPMG. This illegal market costs taxpayers and communities more than EUR11 billion a year in lost tax revenue. If combined, the thousands of transactions made by criminals involved in the illegal tobacco trade would equate to them being the fifth largest cigarette supplier to EU consumers.
PM: 82.16 (+0.92)
Now May Be The Time To Get On Board Japan Tobacco
Alexander Valtsev - at Seeking Alpha - Thu May 21, 3:05PM CDT
JT acquires Logic, the leading independent US e-cigarette company
PR Newswire - Thu Apr 30, 7:00AM CDT
Japan Tobacco Inc. (JT) (TSE: 2914) announced today that it entered into an agreement to acquire Logic Technology Development LLC ("Logic"
, one of the leading US e-cigarette brands. Founded in 2010, Logic sells a full range of high quality rechargeable, ready-to-use and disposable e-cigarettes, including the Logic Pro tank system[1], newly launched in April 2015.
JT Acquires Logic, the Leading Independent US e-Cigarette Company
PR Newswire Europe - Thu Apr 30, 1:16AM CDT
Agreement Gives JT a Global Footprint in the e-Cigarette Market
Cigarettes - Global Strategic Business Report 2015-2020 - Adult Smoking on the Decline in Developed Countries
M2 - Wed Apr 15, 2:52AM CDT
Research and Markets (http://www.researchandmarkets.com/research/cmp4s7/cigarettes) has announced the addition of the "Cigarettes - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Cigarettes in Million Sticks. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2014 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. The report profiles 69 companies including many key and niche players such as: - British American Tobacco - China National Tobacco Corporation - Imperial Tobacco Group PLC - Japan Tobacco Inc. - Philip Morris International Key Topics Covered: 1. OUTLOOK 2. TRENDS & ISSUES 3. COMPETITIVE LANDSCAPE 4. PRODUCT OVERVIEW 5. PRODUCT INTRODUCTIONS 6. RECENT INDUSTRY ACTIVITY 7. FOCUS ON SELECT GLOBAL PLAYERS 8. GLOBAL MARKET PERSPECTIVE Total Companies Profiled: 69 (including Divisions/Subsidiaries - 114) - The United States (19) - Canada (2) - Japan (1) - Europe (47) - France (2) - Germany (6) - The United Kingdom (3) - Italy (3) - Spain (1) - Rest of Europe (32) - Asia-Pacific (Excluding Japan) (31) - Latin America (
- Africa (4) - Middle East (2) For more information visit http://www.researchandmarkets.com/research/cmp4s7/cigarettes About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
PM: 82.16 (+0.92), BTI: 112.52 (+3.75)
Don't cry for tobacco stocks
Seeking Alpha - at Seeking Alpha - Mon Mar 23, 7:09AM CDT
RAI: 76.87 (+0.77), BTI: 112.52 (+3.75), PM: 82.16 (+0.92), LO: 71.40 (-0.33), MO: 51.31 (+0.36), VGR: 23.92 (+0.29)
Renal Anemia Pipeline Review, H1 2015 - 24 Companies & 20 Drug Profiles
M2 - Thu Jul 09, 6:29AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rspq67/renal_anemia) has announced the addition of the "Renal Anemia - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Renal Anemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Renal Anemia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - 3SBio Inc. - Acceleron Pharma, Inc. - Akebia Therapeutics, Inc. - Amgen Inc. - Aprogen, Inc. - Bayer AG - BIOCAD - CCM Duopharma Biotech Bhd. - Daiichi Sankyo Company, Limited - Dong-A Socio Group - FibroGen, Inc. - GlaxoSmithKline plc - Hospira, Inc. - Intas Pharmaceuticals Ltd. - Japan Tobacco Inc. - JCR Pharmaceuticals Co., Ltd. - Jiangsu Hansoh Pharmaceutical Co., Ltd. - Medgenics Inc. - Myungmoon pharmaceutical Co.,Ltd. - Panacea Biotec Limited - Pieris AG - ProMetic Life Sciences Inc. - Sandoz International GmbH - Zydus Cadila Healthcare Limited Drug Profiles - AKB-6548 - daprodustat - darbepoetin alfa (recombinant) - DS-1093 - EPO-018B - epoetin alfa (recombinant) - FG-2216 - FMX-8 - JTZ-951 - MDGN-201 - MM-P01-01 - molidustat - NuPIAO - PBI-1402 - PBI-4050 - PEG-EPO - PRS-080 - Recombinant Protein for Renal Anemia - roxadustat - sotatercept For more information visit http://www.researchandmarkets.com/research/rs...nal_anemia
MDGN: 6.47 (+0.37), AMGN: 154.10 (+2.79), GSK: 42.45 (+0.65), AKBA: 8.83 (+0.09), FGEN: 22.82 (+0.58), XLRN: 30.03 (+0.20)
Cedar Pollen Allergy - Pipeline Review, H1 2015
M2 - Mon Jun 29, 10:21AM CDT
Research and Markets (http://www.researchandmarkets.com/research/qb7s58/cedar_pollen) has announced the addition of the "Cedar Pollen Allergy - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Cedar Pollen Allergy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cedar Pollen Allergy and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Cedar Pollen Allergy - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Cedar Pollen Allergy and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Cedar Pollen Allergy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Cedar Pollen Allergy pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Mentioned - Allergy Therapeutics plc - Anergis SA - Biomay AG - Circassia Pharmaceuticals plc - Immunomic Therapeutics, Inc. - Japan Tobacco Inc. - REGiMMUNE Corporation - Stallergenes S.A. For more information visit http://www.researchandmarkets.com/research/qb...dar_pollen
New study links smoking to more forms of cancer
Seeking Alpha - at Seeking Alpha - Tue Jun 16, 6:06AM CDT
RAI: 76.87 (+0.77), BTI: 112.52 (+3.75), PM: 82.16 (+0.92), LO: 71.40 (-0.33), MO: 51.31 (+0.36), VGR: 23.92 (+0.29)
Japan Tobacco International | JT Publishes Sustainability Report FY2014
M2 - Mon Jun 15, 8:26AM CDT
Japan Tobacco Inc. (JT) (TSE: 2914) has published the JT Group Sustainability Report FY2014, outlining its sustainability initiatives and performance for the year ending 31st December, 2014.
Philip Morris Offers Attractive Pricing And Growth Potential
J Mintzmyer - at Seeking Alpha - Thu Jun 11, 10:03AM CDT
PM: 82.16 (+0.92), BTI: 112.52 (+3.75)
WisdomTree Japan-Themed ETF Focuses on Growth, Quality
at The Street - Mon Jun 08, 7:22PM CDT
WisdomTree's Japan Dividend Growth ETF is the company's 10th Japan-themed ETF, said its associate director of research.
DXJ: 56.33 (+1.54), JDG: 23.69 (unch), NTT: 36.75 (+1.49), DCM: 19.16 (+0.26)
Global Pollen Allergy Pipeline Review, H1 2015 - 14 Companies & 31 Drug Profiles
M2 - Fri Jun 05, 5:06AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3crnf4/pollen_allergy) has announced the addition of the "Pollen Allergy - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Pollen Allergy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pollen Allergy and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - ALK-Abello A/S - Allergopharma Joachim Ganzer KG - Allergy Therapeutics plc - Anergis SA - Biomay AG - BioTech Tools s.a. - Circassia Pharmaceuticals plc - HAL Allergy BV - Immunomic Therapeutics, Inc. - Japan Tobacco Inc. - Laboratorios LETI S.L. - REGiMMUNE Corporation - Roxall Medizin GmbH - Stallergenes S.A. Drug Profiles - ALK Birch Pollen Vaccine - AllerG - Allergen Extract Of Phleum Pratense - Allergen for Birch Pollen Induced Allergic Rhinitis and Rhinoconjunctivitis - Allergen for Pollen Grass Allergy Induced Allergic Rhinitis and Rhinoconjunctivitis - AllerJ - AllerT - ASP-4070 - Avanz Phleum Pratense - Birch-SPIRE - BM-31 - BM-32 - clustoid wiesenlieschgras - Drug for Birch Pollen Allergy - Drug for Japanese Cedar Pollen Allergy - Drugs for Cedar Pollen Allergy - gpASIT TM - grass allergy vaccine - Japanese cedar hypoallergenic vaccine - JCC-LAMP-Vax - MC-LAMP-Vax - Multi-LAMP-Vax - PL-102 - Pollinex Quattro - rBet v1 - rBet v1-FV - RGI-1001 - timothy grass pollen allergen extract - TO-206 - Vaccine for Asthma, Grass Pollen Allergy and Allergic Rhino-Conjunctivitis - Vaccine for Cedar Pollen Allergy For more information visit http://www.researchandmarkets.com/research/3c...en_allergy
Philip Morris: A New Challenge Emerges
Albert Alfonso - at Seeking Alpha - Wed Jun 03, 1:22PM CDT
PM: 82.16 (+0.92), BTI: 112.52 (+3.75), MO: 51.31 (+0.36)
Reduction seen for massive Canadian tobacco damages award
Seeking Alpha - at Seeking Alpha - Wed Jun 03, 7:13AM CDT
BTI: 112.52 (+3.75)
Tobacco companies face large class-action payments in Canada
Seeking Alpha - at Seeking Alpha - Tue Jun 02, 8:04AM CDT
PM: 82.16 (+0.92), BTI: 112.52 (+3.75)
European Stocks Drop as Greece Debt Talks Get Serious; Inflation Rises
at The Street - Tue Jun 02, 5:37AM CDT
European stock markets declined Tuesday on Greek debt worries even as better-than-expected eurozone consumer price data suggested that government bond-buying had staved off Japanese-style deflation.
PM: 82.16 (+0.92), BTI: 112.52 (+3.75)
Black market tobacco trade increases in the UK
M2 - Thu May 28, 9:33AM CDT
The UK has seen nearly a 50% rise in the consumption of counterfeit and contraband (C&C) cigarettes in 2014, the second highest increase across the whole of the EU according to a KPMG report published today.
PM: 82.16 (+0.92)
56.6 Billion Illegal Cigarettes Consumed in the EU in 2014, Worth More Than EUR11bn in Lost Tax Revenue
Business Wire - Thu May 28, 3:09AM CDT
The scale of the illegal trade in cigarettes remains sizeable in the European Union (EU), with a total of 56.6 billion illegal cigarettes consumed in 2014, representing 10.4% of total consumption, according to the latest annual report by KPMG. This illegal market costs taxpayers and communities more than EUR11 billion a year in lost tax revenue. If combined, the thousands of transactions made by criminals involved in the illegal tobacco trade would equate to them being the fifth largest cigarette supplier to EU consumers.
PM: 82.16 (+0.92)
Now May Be The Time To Get On Board Japan Tobacco
Alexander Valtsev - at Seeking Alpha - Thu May 21, 3:05PM CDT
JT acquires Logic, the leading independent US e-cigarette company
PR Newswire - Thu Apr 30, 7:00AM CDT
Japan Tobacco Inc. (JT) (TSE: 2914) announced today that it entered into an agreement to acquire Logic Technology Development LLC ("Logic"
, one of the leading US e-cigarette brands. Founded in 2010, Logic sells a full range of high quality rechargeable, ready-to-use and disposable e-cigarettes, including the Logic Pro tank system[1], newly launched in April 2015. JT Acquires Logic, the Leading Independent US e-Cigarette Company
PR Newswire Europe - Thu Apr 30, 1:16AM CDT
Agreement Gives JT a Global Footprint in the e-Cigarette Market
Cigarettes - Global Strategic Business Report 2015-2020 - Adult Smoking on the Decline in Developed Countries
M2 - Wed Apr 15, 2:52AM CDT
Research and Markets (http://www.researchandmarkets.com/research/cmp4s7/cigarettes) has announced the addition of the "Cigarettes - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Cigarettes in Million Sticks. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2014 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. The report profiles 69 companies including many key and niche players such as: - British American Tobacco - China National Tobacco Corporation - Imperial Tobacco Group PLC - Japan Tobacco Inc. - Philip Morris International Key Topics Covered: 1. OUTLOOK 2. TRENDS & ISSUES 3. COMPETITIVE LANDSCAPE 4. PRODUCT OVERVIEW 5. PRODUCT INTRODUCTIONS 6. RECENT INDUSTRY ACTIVITY 7. FOCUS ON SELECT GLOBAL PLAYERS 8. GLOBAL MARKET PERSPECTIVE Total Companies Profiled: 69 (including Divisions/Subsidiaries - 114) - The United States (19) - Canada (2) - Japan (1) - Europe (47) - France (2) - Germany (6) - The United Kingdom (3) - Italy (3) - Spain (1) - Rest of Europe (32) - Asia-Pacific (Excluding Japan) (31) - Latin America (
- Africa (4) - Middle East (2) For more information visit http://www.researchandmarkets.com/research/cmp4s7/cigarettes About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. PM: 82.16 (+0.92), BTI: 112.52 (+3.75)
Don't cry for tobacco stocks
Seeking Alpha - at Seeking Alpha - Mon Mar 23, 7:09AM CDT
RAI: 76.87 (+0.77), BTI: 112.52 (+3.75), PM: 82.16 (+0.92), LO: 71.40 (-0.33), MO: 51.31 (+0.36), VGR: 23.92 (+0.29)
